{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:41:59Z","timestamp":1780047719508,"version":"3.53.1"},"reference-count":53,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Inhibitors of vascular endothelial growth factors are used to treat a myriad of retinal conditions, including exudative age-related macular degeneration (AMD), diabetic macular oedema (DME) and diabetic retinopathy. Although effective, long-term efficacy is limited by the need for frequent and invasive intravitreal injections. The quest for sustained action therapeutics that can be delivered to target tissue in the least invasive manner is an arduous endeavour that has ended in premature failure for several technologies in Phase II or III trials. Nevertheless, there have been promising preclinical studies, and more are on the horizon: port delivery systems for the treatment of exudative AMD have entered Phase III trials and a wide array of preclinical studies have demonstrated the potential for nanoparticles, such as liposomes, dendrimers and cell penetrating peptides to deliver therapeutics into the posterior segment via minimally invasive routes. In this review, we discuss the challenges posed by ocular barriers for drug penetration and present the recent advancements of the most pertinent drug delivery platforms with a focus on the treatment of exudative AMD and DME.<\/jats:p>","DOI":"10.1136\/bjophthalmol-2018-313462","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T21:26:30Z","timestamp":1556659590000},"page":"1356-1360","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema"],"prefix":"10.1136","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-2016","authenticated-orcid":false,"given":"Chee Wai","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina T","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"key":"2020050713022481000_103.10.1356.1","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"2020050713022481000_103.10.1356.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"2020050713022481000_103.10.1356.3","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(93)90141-S"},{"key":"2020050713022481000_103.10.1356.4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.1986.2.67","article-title":"Topical ocular drug delivery: recent developments and future challenges","volume":"2","author":"Lee","year":"1986","journal-title":"J Ocul Pharmacol"},{"key":"2020050713022481000_103.10.1356.5","first-page":"215","article-title":"Size-dependent diffusion of dextrans in excised porcine corneal stroma","volume":"12","author":"Rajapakshal","year":"2015","journal-title":"Mol Cell Biomech"},{"key":"2020050713022481000_103.10.1356.6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.2015.0047","article-title":"Recent advances in topical ocular drug delivery","volume":"32","author":"Yellepeddi","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"2020050713022481000_103.10.1356.7","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.5.5.567"},{"key":"2020050713022481000_103.10.1356.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00129-4"},{"key":"2020050713022481000_103.10.1356.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00344-4"},{"key":"2020050713022481000_103.10.1356.10","doi-asserted-by":"publisher","DOI":"10.1021\/js9802594"},{"key":"2020050713022481000_103.10.1356.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"key":"2020050713022481000_103.10.1356.12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jop.2012.0138","article-title":"The vitreous humor as a barrier to nanoparticle distribution","volume":"29","author":"Mains","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"2020050713022481000_103.10.1356.13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ymthe.2016.10.008","article-title":"Improved intravitreal AAV-mediated inner retinal gene transduction after surgical internal limiting membrane peeling in cynomolgus monkeys","volume":"25","author":"Takahashi","year":"2017","journal-title":"Mol Ther"},{"key":"2020050713022481000_103.10.1356.14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/978-1-4614-4711-5_3","article-title":"The Blood-Retina barrier: tight junctions and barrier modulation","volume":"763","author":"Campbell","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"2020050713022481000_103.10.1356.15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jfb4010014","article-title":"Design and in vitro biocompatibility of a novel ocular drug delivery device","volume":"4","author":"Gooch","year":"2013","journal-title":"J Funct Biomater"},{"key":"2020050713022481000_103.10.1356.16","first-page":"506","article-title":"NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells","volume":"10","author":"Emerich","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"2020050713022481000_103.10.1356.17","unstructured":"U.S. Department of Health and Human Services . Study of the intravitreal implantation of NT-503-3 encapsulated cell technology (ECT) for the treatment of recurrent choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02228304 [Accessed 19th Feb 2019]."},{"key":"2020050713022481000_103.10.1356.18","unstructured":"U.S. Department of Health and Human Services . A depot formulation of sunitinib malate (GB-102) in subjects with neovascular (Wet) age-related macular degeneration. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03249740 [Accessed 21st Feb 2019]."},{"key":"2020050713022481000_103.10.1356.19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ophtha.2014.09.036","article-title":"Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration","volume":"122","author":"Csaky","year":"2015","journal-title":"Ophthalmology"},{"key":"2020050713022481000_103.10.1356.20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bcp.13794","article-title":"The developing regorafenib eye drops for neovascular age-related macular degeneration (DREAM) study: an open-label phase II trial","volume":"85","author":"Joussen","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2020050713022481000_103.10.1356.21","unstructured":"GlobeNewswire, Inc . Ohr pharmaceutical Announces efficacy results from the MAKO study in Wet-AMD. Available: https:\/\/globenewswire.com\/news-release\/2018\/01\/05\/1284092\/0\/en\/Ohr-Pharmaceutical-Announces-Efficacy-Results-from-the-MAKO-Study-in-Wet-AMD.html"},{"key":"2020050713022481000_103.10.1356.22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/13543784.2015.961601","article-title":"Drugs in phase II clinical trials for the treatment of age-related macular degeneration","volume":"24","author":"Tolentino","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"2020050713022481000_103.10.1356.23","unstructured":"U.S. Department of Health and Human Services . LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02355028 [Accessed 20th Feb 2019]."},{"key":"2020050713022481000_103.10.1356.24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.18433\/J3CP55","article-title":"Liposomal drug delivery: a versatile platform for challenging clinical applications","volume":"17","author":"Madni","year":"2014","journal-title":"J Pharm Pharm Sci"},{"key":"2020050713022481000_103.10.1356.25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/08820138009065997","article-title":"Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own","volume":"9","author":"van Rooijen","year":"1980","journal-title":"Immunol Commun"},{"key":"2020050713022481000_103.10.1356.26","first-page":"4817","article-title":"Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro","volume":"52","author":"Ahmad","year":"1992","journal-title":"Cancer Res"},{"key":"2020050713022481000_103.10.1356.27","doi-asserted-by":"publisher","DOI":"10.2174\/138920012798356934"},{"key":"2020050713022481000_103.10.1356.28","first-page":"893","article-title":"Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes","volume":"28","author":"Barza","year":"1987","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050713022481000_103.10.1356.29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/jop.2000.16.511","article-title":"Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes","volume":"16","author":"Gupta","year":"2000","journal-title":"J Ocul Pharmacol Ther"},{"key":"2020050713022481000_103.10.1356.30","doi-asserted-by":"crossref","unstructured":"Joseph RR , Tan DWN , Ramon MRM , et al . Characterization of liposomal carriers for the trans-scleral transport of ranibizumab. Sci Rep 2017;7.doi:10.1038\/s41598-017-16791-7","DOI":"10.1038\/s41598-017-16791-7"},{"key":"2020050713022481000_103.10.1356.31","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"2020050713022481000_103.10.1356.32","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181a2f42a"},{"key":"2020050713022481000_103.10.1356.33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijpharm.2018.07.030","article-title":"Dendrimers: a versatile nanocarrier for drug delivery and targeting","volume":"548","author":"Sherje","year":"2018","journal-title":"Int J Pharm"},{"key":"2020050713022481000_103.10.1356.34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302579"},{"key":"2020050713022481000_103.10.1356.35","unstructured":"Retina Today . Long-acting anti-VEGF delivery. Available: http:\/\/retinatoday.com\/2014\/08\/long-acting-anti-vegf-delivery [Accessed 19th Feb 2019]."},{"key":"2020050713022481000_103.10.1356.36","unstructured":"Hoffmann-La Roche Ltd . Investor update. Available: https:\/\/www.roche.com\/investors\/updates\/inv-update-2018-07-26b.htm [Accessed 19th Feb 2019]."},{"key":"2020050713022481000_103.10.1356.37","doi-asserted-by":"crossref","unstructured":"Humayun M , Santos A , Altamirano JC , et al . Implantable MicroPump for drug delivery in patients with diabetic macular edema. Transl Vis Sci Technol 2014;3.doi:10.1167\/tvst.3.6.5","DOI":"10.1167\/tvst.3.6.5"},{"key":"2020050713022481000_103.10.1356.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.01.003"},{"key":"2020050713022481000_103.10.1356.39","doi-asserted-by":"publisher","DOI":"10.1002\/psc.2672"},{"key":"2020050713022481000_103.10.1356.40","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/mp400681n","article-title":"Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery","volume":"11","author":"Liu","year":"2014","journal-title":"Mol. Pharmaceutics"},{"key":"2020050713022481000_103.10.1356.41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/jop.2013.0247","article-title":"Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study","volume":"31","author":"Beydoun","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"2020050713022481000_103.10.1356.42","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1167\/iovs.16-20072","article-title":"Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides","volume":"58","author":"de Cogan","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050713022481000_103.10.1356.43","first-page":"1140","article-title":"Tat PTD-endostatin: a novel anti-angiogenesis protein with ocular barrier permeability via eye-drops","volume":"2015","author":"Zhang","year":"1850","journal-title":"Biochim Biophys Acta"},{"key":"2020050713022481000_103.10.1356.44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.biomaterials.2016.09.022","article-title":"Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution","volume":"112","author":"Chen","year":"2017","journal-title":"Biomaterials"},{"key":"2020050713022481000_103.10.1356.45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2017.09.036","article-title":"High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases","volume":"266","author":"Suda","year":"2017","journal-title":"J Control Release"},{"key":"2020050713022481000_103.10.1356.46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2018.06.023","article-title":"Cell penetrating peptides in ocular drug delivery: state of the art","volume":"284","author":"Pescina","year":"2018","journal-title":"J Control Release"},{"key":"2020050713022481000_103.10.1356.47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","article-title":"Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration","volume":"22","author":"Hussain","year":"2017","journal-title":"Expert Opinion on Emerging Drugs"},{"key":"2020050713022481000_103.10.1356.48","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"2020050713022481000_103.10.1356.49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","article-title":"Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial","volume":"177","author":"Constable","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"2020050713022481000_103.10.1356.50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"2020050713022481000_103.10.1356.51","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301878"},{"key":"2020050713022481000_103.10.1356.52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.2016.117","article-title":"Lentiviral vector gene transfer of Endostatin\/Angiostatin for macular degeneration (GEM) study","volume":"28","author":"Campochiaro","year":"2017","journal-title":"Human Gene Therapy"},{"key":"2020050713022481000_103.10.1356.53","unstructured":"U.S. Department of Health and Human Services . RGX-314 gene therapy for neovascular AMD trial. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03066258 [Accessed 21st Feb 2019]."}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-313462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:59:18Z","timestamp":1601110758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-313462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,9,19]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/bjophthalmol-2018-313462"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313462","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]}}}